PAP
TENX icon

Persistent Asset Partners’s Tenax Therapeutics TENX Stock Holding History

Persistent Asset Partners’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$930K Sell
58,182
-7,090
-11% -$95.9K 0.35% 70
2025
Q4 		$796K Buy
+65,272
New +$568K 0.36% 77

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Persistent Asset Partners's TENX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Tenax Therapeutics (TENX) stake by 11% in Q1 2026, selling an estimated $95.9K and leaving 58,182 shares worth $930K. The position accounts for 0.35% of the portfolio, ranked #70.

Persistent Asset Partners first reported a position in TENX in Q4 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Persistent Asset Partners held 58,182 shares of Tenax Therapeutics worth $930K as of Q1 2026.
  • Persistent Asset Partners sold 7,090 Tenax Therapeutics shares in Q1 2026, an estimated $95.9K.
  • Tenax Therapeutics made up 0.35% of Persistent Asset Partners's portfolio in Q1 2026, its #70 holding.
  • Persistent Asset Partners first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.